JasonMichaelMelearMD

PubMed

• Author Correction: Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
  R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason ...> ;Nature Communications. 2023 Aug 7
• 4 citations
  Dose escalation and expansion cohorts in patients with advanced breast cancer in a Phase I study of the CDK7-inhibitor samuraciclib.
  R C Coombes, Sacha Howell, Simon R Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason ...> ;Nature Communications. 2023 Jul 24
• 2 citations
  Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United States.
  Jorge J Castillo, Edwin C Kingsley, Mohit Narang, Habte A Yimer, Constantin A Dasanu, Jason M Melear, Morton Coleman, Charles M Farber, Jonah Shulman, Emily H Mantovan...> ;Ejhaem. 2023 Feb 1
• 3 citations
  Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma.
  Paul M Barr, Stephen D Smith, Mark J Roschewski, Susan M O'Brien, Jeff P Sharman, Jason M Melear, Priti Patel, Roser Calvo, Helen Yang, Stephen E Spurgeon> ;Leukemia & Lymphoma. 2022 Jul 1
• 7 citations
  Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study.
  Habte Yimer, Jason Melear, Edward Faber, William I Bensinger, John M Burke, Mohit Narang, Don Stevens, Kathleen S Gray, Yana Lutska, Padma Bobba, Keqin Qi, Daniela Hoe...> ;Leukemia & Lymphoma. 2022 Oct 1
• 17 citations
  A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
  Ruth Plummer, Emma Dean, Hendrik-Tobias Arkenau, Charles H. Redfern, Alexander I. Spira, Jason M. Melear, Ki Y. Chung, Jordi Ferrer-Playan, Thomas Goddemeier, Giuseppe...> ;Lung Cancer. 2021 Dec 1
• 46 citations
  Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study
  Habte A. Yimer, Jason M. Melear, Edward A. Faber, William I. Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Sriya Gunawardena, Yana Lutska, Keqin Qi, Jon Ukro...> ;British Journal of Haematology. 2019 May 1
• 55 citations
  Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders.
  Jason M. Melear, Robert M. Goldstein, Marlon F. Levy, Ernesto P. Molmenti, Barry Cooper, George J. Netto, Goran B. Klintmalm, Marvin J. Stone> ;Transplantation. 2002 Oct 27
• Join now to see all

Abstracts/Posters

• Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study
  Jason M. Melear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-Free Survival (PFS) Following Dara Plus Cyclophosphamide, Bortezom...
  Jason M. Melear, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

• Lyra: A Phase 2 Study of Daratumumab (Dara) Plus Cyclophosphamide, Bortezomib, and Dexamethasone (Cybord) in Newly Diagnosed and Relapsed Patients (Pts) with Multiple ... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018